<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="1538" language="x-unspecified"/>
    <type:PFSMean xmi:id="13" sofa="6" begin="1028" end="1038"/>
    <type:PFSMean xmi:id="17" sofa="6" begin="1043" end="1053"/>
    <type:ORR xmi:id="21" sofa="6" begin="1094" end="1097"/>
    <type:ORR xmi:id="25" sofa="6" begin="1102" end="1105"/>
    <type:OSMean xmi:id="29" sofa="6" begin="1123" end="1134"/>
    <type:OSMean xmi:id="33" sofa="6" begin="1139" end="1152"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="BACKGROUND: Metastatic breast cancer (MBC) patients with rapid disease relapse&#13;&#10;after neo/adjuvant chemotherapy including anthracyclines and taxanes have limited&#13;&#10;treatment options and their efficacy is marginal. Two phase III studies compared &#13;&#10;ixabepilone plus capecitabine vs. capecitabine alone as first-line treatment in&#13;&#10;MBC patients pretreated with anthracyclines and taxanes in the neo/adjuvant&#13;&#10;setting. Here we report the efficacy and safety of these treatments in a&#13;&#10;prespecified subset of patients whose disease relapsed within 12 months.&#13;&#10;PATIENTS AND METHODS: Of 1973 patients across two studies, 293 relapsed within 12&#13;&#10;months of neo/adjuvant treatment and received ixabepilone plus capecitabine (n = &#13;&#10;149) or capecitabine alone (n = 144) as first-line chemotherapy for MBC. Analysis&#13;&#10;included progression-free survival (PFS), overall survival (OS), objective&#13;&#10;response rate (ORR) and toxicity.&#13;&#10;RESULTS: In 293 patients, ixabepilone plus capecitabine, as compared to&#13;&#10;capecitabine alone, increased PFS (median: 5.6 months vs. 2.8 months; hazard&#13;&#10;ratio, 0.58; p &lt; 0.0001), ORR (46% vs. 24%) and OS (median: 15.1 months vs. 12.5 &#13;&#10;months; hazard ratio, 0.84; p = 0.208). Major toxicities of this regimen included&#13;&#10;neuropathy, neutropenia and hand-foot syndrome, but were manageable.&#13;&#10;CONCLUSIONS: Patients with breast cancer with early relapse following&#13;&#10;neo/adjuvant treatment with anthracyclines and taxanes may benefit from&#13;&#10;ixabepilone plus capecitabine. (ClinicalTrials.gov identifiers: NCT00080301 and&#13;&#10;NCT00082433.)."/>
    <cas:View sofa="6" members="1 13 17 21 25 29 33"/>
</xmi:XMI>
